What we are studying
The purpose of this study is to learn if adding an experimental drug, veliparib (also known as ABT-888), to a usual treatment is better than the usual treatment alone. To be better than the usual treatment, the addition of the experimental drug to the usual treatment needs to shrink more of the cancer than the usual treatment alone.
Another purpose of this study is to test the good and bad effects of veliparib when added to the usual treatment. Veliparib may shrink your cancer but it can also cause side effects. Veliparib is not FDA-approved for treating cancer but it is being used in other clinical trials. In this study, veliparib is considered to be experimental.
Parking will be validated for study-related visits.